SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis.

NO-Rosa5 (chloride) is a photocontrollable NO donor. NO-Rosa5 (chloride) is made up of the fluorescent dye rosamie that functions as the light-harvesting group.

Papaveroline is a Fyn Tyrosine Kinase inhibitor. Papaveroline can be used for the research of neurological disease, such as Alzheimer's disease (AD).

ML-20, Malabaricone C analogue, is a autophagy inhibitor and radiosensitizer. ML-20 inhibits cell growth, induces cell apoptosis . ML-20 induces DNA double-strand breaks, loss of mitochondrial membrane potential (MMP), and lysosomal membrane permeabilization (LMP). ML-20 induces endoplasmic reticulum stress and concurrent inhibition of autophagy flux due to LMP .

SB-583355 (Compound 56) is a potent G2A antagonist. SB-583355 can be prepared by a Suzuki reaction between 4-methoxyphenyl boronic acid and 3-bromo-4-hydroxybenzoic acid following the conditions followed by an amide coupling reaction. SB-583355 blocks the activation of G2A mediated either by 9-HOPE or T-10148 in human G2A expressing CHO-K1 cells. SB-583355 can be studied in research for inflammation, myeloid leukemia, and neuropathic pain.

Vilanterol (GW642444) acetate is a long-acting β2 adrenergic receptor agonist. Vilanterol acetate has pEC50 values for β2-AR, β1-AR, and β3-AR of 9.4, 6.4, and 6.1, respectively. Vilanterol acetate selectively activates airway β2 adrenergic receptors, increases cAMP and thus relaxes bronchial smooth muscle. Vilanterol acetate can be used in asthma research[1][2].

LM-189, a G protein alpha subunit I (Gαi)-biased agonist, is a Gαi-biased ligand of β2-adrenergic receptor (β2AR). LM-189 stabilizes a distinct conformation in TM6 and increases the dynamics of ICL2. LM-189 can be used to develop the Gαi-biased β2AR agonists.

LM-189 free base, a G protein alpha subunit I (Gαi)-biased agonist, is a Gαi-biased ligand of β2-adrenergic receptor (β2AR). LM-189 free base stabilizes a distinct conformation in TM6 and increases the dynamics of ICL2. LM-189 free base can be used to develop the Gαi-biased β2AR agonists.

RD0392 (Compound 5) is a competitive tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor (IC50=1.3 nM). RD0392 is promising for research of neurodegenerative diseases like Alzheimer’s.

Salvianolic acid A derivative-1 (Compound SAA-30) is a orally active derivative of Salvianolic acid A. Salvianolic acid A derivative-1 binds to transgelin with a KD of 2.39 μM. Salvianolic acid A derivative-1 promotes cell contractions by facilitating the aggregation of actin. Salvianolic acid A derivative-1 can be used for prevention of myocardial ischemia or other diseases associated with IR tissue injuries.

HEAL-116 is a potent, specific and orally active 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) inhibitor with an IC50 of 1.18 μM and a KD of 1.32 μM. HEAL-116 inhibits DHEA metabolism and DHEA-induced target gene expression and cell proliferation. HEAL-116 can be used for cancer research, such as prostate cancer.

PYO12 is a 3-phenyl-4-phenoxypyrazole type antibacterial compound. PYO12 exhibits selective activity against Gram-positive bacteria with MIC for S. aureus, B. subtilis, S. pneumoniae, and MRSA of 1, 1, 1, and 4 μg/mL respectively. PYO12 has no activity against Gram-negative bacteria. PYO12 can significantly increase bacterial membrane permeability and significantly upregulate cell wall stress-related genes, possibly by binding to the C55-PP part of lipid II. PYO12 shows a concentration-dependent bactericidal effect, has low toxicity to mammalian cells, and does not cause hemolysis. PYO12 can be used to develop new antibiotics targeting bacterial cell wall synthesis.

NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improves the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke.

CNV-dopamine is a photoreleasable D2 receptor-selective agonist. CNV-dopamine activates D2 receptors and induces G protein-coupled inwardly rectifying potassium (GIRK) currents. CNV-dopamine is promising for research of disorders like Parkinson’s disease and addiction.

CH091138 is a potent and selective KRASG12D PROTAC degrader with DC50s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous KRASG12D but not KRASWT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the studies of pancreatic cancer and colon cancer.

Pezulepistat is a macrocyclic broad spectrum antibiotic. Pezulepistat can be studied for microbial infections such as gram-negative bacterial infections.

5-Hydroxy-6-methoxy (S)-duloxetine maleate is an orally active and brain-penetrant serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor with antidepressant and analgesic activities. 5-Hydroxy-6-methoxy (S)-duloxetine maleate is promising for research of psychiatric and neurological disorders such as depression, diabetic neuropathic pain, generalized anxiety disorder, and fibromyalgia.

KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a Ki of 2.7 μM.

CU-TZD-20 is a PARP-1 inhibitor. CU-TZD-20 has a high affinity for binding to the PARP-1 catalytic domain and good structural stability. CU-TZD-20 competitively occupies NAD+ binding sites and forms stable interactions with key catalytic residues. CU-TZD-20 can be used for cancer research.

Zelandopam (anhydrous) (YM435 (anhydrous)) is an orally active and selective agonist of the dopamine D1 receptor. Zelandopam (anhydrous) possesses potent renal vasodilatory properties and can effectively alleviate Cisplatin-induced acute renal failure.

AM11542 is a orthosteric agonist of cannabinoid receptor 1 (CB1), with a reported binding affinity (Ki) of 0.11 nM. AM11542 can be used for the study of CB1 receptor activation and related allosteric modulation mechanisms.

SMARCA2 Ligand-Linker Conjugate-4 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for SMARCA2 and a PROTAC linker, which recruits E3 ligases. SMARCA2 Ligand-Linker Conjugate-4 can be used for synthesis of PROTAC SMARCA2 degrader-35.

(S,S,S)-VH032-cyclopropane-F is a ligand for E3 ubiquitin ligases. (S,S,S)-VH032-cyclopropane-F can be linked to target protein ligands via a linker to form the PROTAC cis-VZ185.

(S)-SCH-23390 (hydrochloride) is the S-enantiomer of SCH-23390. SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively).

Votoplam (PTC518) hydrochloride is an HTT gene regulator with an IC50 ≤ 0.1 μM. Votoplam hydrochloride can be used in the research of Huntington's disease.

L-703717 is a NMDA receptor antagonist. L-703717 preferentially binds to cerebellar-specific NMDA receptors consisting of a GluRepsilon3 subunit and eventually accumulates in rodent cerebellum. L-703717 can be used for the research of neurological disease.

SMARCA2/4-ligand-6 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). SMARCA2/4-ligand-6 can be used for the synthesis of SMARCA2/4-ligand-6.

WEIZ-WX-04-008 (Compound 1) is a covalent Lysine-targeting MKK7 inhibitor with IC50 of 738 nM.

CPA 926 is a prodrug of Esculetin and is orally active. CPA 926 can inhibit the production of MMP in cartilage explants. CPA 926 can be used for the research of inflammation, such as experimental osteoarthritis.

LC-PDin06 is a selective PRDX1 inhibitor with an IC50 of 0.042 μM. LC-PDin06, a Celastrol derivative, shows potent antiproliferative activity against colorectal cancer cells by significantly increasing ROS levels.